- Home
- RAMP vs AKRO Comparison
RAMP vs AKRO Comparison
Compare RAMP & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAMP
- AKRO
- Stock Information
- Founded
- RAMP 2018
- AKRO 2017
- Country
- RAMP United States
- AKRO United States
- Employees
- RAMP N/A
- AKRO N/A
- Industry
- RAMP EDP Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- RAMP Technology
- AKRO Health Care
- Exchange
- RAMP Nasdaq
- AKRO Nasdaq
- Market Cap
- RAMP 1.8B
- AKRO 3.6B
- IPO Year
- RAMP 1987
- AKRO 2019
- Fundamental
- Price
- RAMP $27.17
- AKRO $46.27
- Analyst Decision
- RAMP Buy
- AKRO Strong Buy
- Analyst Count
- RAMP 7
- AKRO 8
- Target Price
- RAMP $39.00
- AKRO $80.38
- AVG Volume (30 Days)
- RAMP 620.0K
- AKRO 915.6K
- Earning Date
- RAMP 11-05-2025
- AKRO 11-07-2025
- Dividend Yield
- RAMP N/A
- AKRO N/A
- EPS Growth
- RAMP 147.00
- AKRO N/A
- EPS
- RAMP 0.22
- AKRO N/A
- Revenue
- RAMP $764,441,000.00
- AKRO N/A
- Revenue This Year
- RAMP $10.65
- AKRO N/A
- Revenue Next Year
- RAMP $8.70
- AKRO N/A
- P/E Ratio
- RAMP $123.53
- AKRO N/A
- Revenue Growth
- RAMP 12.16
- AKRO N/A
- 52 Week Low
- RAMP $22.82
- AKRO $21.34
- 52 Week High
- RAMP $36.08
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- RAMP 46.56
- AKRO 51.29
- Support Level
- RAMP $26.15
- AKRO $41.80
- Resistance Level
- RAMP $27.08
- AKRO $45.44
- Average True Range (ATR)
- RAMP 0.67
- AKRO 1.97
- MACD
- RAMP 0.11
- AKRO 0.06
- Stochastic Oscillator
- RAMP 41.86
- AKRO 75.76
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.